Literature DB >> 17258673

Experimental treatments for acute ischaemic stroke.

Ralph L Sacco1, Ji Y Chong, Shyam Prabhakaran, Mitchell S V Elkind.   

Abstract

Treatments for acute ischaemic stroke continue to evolve. Experimental approaches to restore cerebral perfusion include techniques to augment recanalising therapies, including combination of antiplatelet agents with intravenous thrombolysis, bridging therapy of combining intravenous with intra-arterial thrombolysis, and trials of new thrombolytic agents. Trials with MRI selection criteria are underway to expand the window of opportunity for thrombolysis. Sonothrombolysis and novel endovascular mechanical devices to retrieve or dissolve acute cerebral occlusions are being tested. Approaches to improve cerebral perfusion with other devices and induced hypertension are also being considered. Although numerous neuroprotective agents have not shown benefit, trials of hypothermia, magnesium, caffeinol, high doses of statins, and albumin are continuing. The findings of these randomised trials are anticipated to allow improved treatment of patients with acute stroke.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17258673     DOI: 10.1016/S0140-6736(07)60155-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  28 in total

Review 1.  Therapeutic effects of traditional herbal medicine on cerebral ischemia: a perspective of vascular protection.

Authors:  Youngmin Bu; Kyungjin Lee; Hyuk-Sang Jung; Sang-Kwan Moon
Journal:  Chin J Integr Med       Date:  2013-10-30       Impact factor: 1.978

2.  Dynamic metabolites profile of cerebral ischemia/reperfusion revealed by (1)H NMR-based metabolomics contributes to potential biomarkers.

Authors:  Yun Wang; Yi-Gang Wang; Teng-Fei Ma; Mei Li; Shu-Ling Gu
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

3.  Beneficial Effects of Delayed P7C3-A20 Treatment After Transient MCAO in Rats.

Authors:  Zachary B Loris; Justin R Hynton; Andrew A Pieper; W Dalton Dietrich
Journal:  Transl Stroke Res       Date:  2017-08-25       Impact factor: 6.829

4.  Ginsenoside rd in experimental stroke: superior neuroprotective efficacy with a wide therapeutic window.

Authors:  Ruidong Ye; Xiangwei Kong; Qianzi Yang; Yunxia Zhang; Junliang Han; Ping Li; Lize Xiong; Gang Zhao
Journal:  Neurotherapeutics       Date:  2011-07       Impact factor: 7.620

5.  GLP-1R activation for the treatment of stroke: updating and future perspectives.

Authors:  Vladimer Darsalia; David Nathanson; Thomas Nyström; Thomas Klein; Åke Sjöholm; Cesare Patrone
Journal:  Rev Endocr Metab Disord       Date:  2014-09       Impact factor: 6.514

Review 6.  Tissue-type plasminogen activator as a therapeutic target in stroke.

Authors:  Iordanis Gravanis; Stella E Tsirka
Journal:  Expert Opin Ther Targets       Date:  2008-02       Impact factor: 6.902

Review 7.  Cell adhesion molecules and ischemic stroke.

Authors:  Gokhan Yilmaz; D Neil Granger
Journal:  Neurol Res       Date:  2008-10       Impact factor: 2.448

8.  Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models.

Authors:  Bénédicte Menn; Stéphane Bach; Teri L Blevins; Mark Campbell; Laurent Meijer; Serge Timsit
Journal:  PLoS One       Date:  2010-08-12       Impact factor: 3.240

9.  Pathophysiological interference with neurovascular coupling - when imaging based on hemoglobin might go blind.

Authors:  Ute Lindauer; Ulrich Dirnagl; Martina Füchtemeier; Caroline Böttiger; Nikolas Offenhauser; Christoph Leithner; Georg Royl
Journal:  Front Neuroenergetics       Date:  2010-10-04

Review 10.  Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review.

Authors:  Prabal K Chatterjee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-22       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.